TY -的T1 -衰减流感样症状和改善细胞免疫治疗与长期防治JF -欧洲呼吸杂志》乔欧元和J SP - 1535 LP - 1541 - 10.1183 / 09031936.97.10071535六世- 10 - 7非盟- De植物年代AU -格拉希,C盟——Carati L Y1 - 1997/07/01 UR - //www.qdcxjkg.com/content/10/7/1535.abstract N2 -防治(NAC),一个模拟和减少谷胱甘肽的前体,已在临床使用超过30年作为粘液溶解药物。一般来说，它也被提议用于和/或用于治疗和/或预防几种呼吸系统疾病和涉及氧化应激的疾病。本研究的目的是评价NAC长期治疗对流感和流感样发作的影响。共262名男女受试者(78% >或= 65岁，62%患有非呼吸系统慢性退行性疾病)纳入一项涉及20个意大利中心的随机、双盲试验。他们随机接受安慰剂或NAC片(600 mg)，每天两次，持续6个月。患有慢性呼吸道疾病的患者不符合条件，以避免NAC对呼吸道症状的影响可能造成混淆。NAC治疗耐受性良好，并导致流感样发作的频率、严重程度和卧床时间显著减少。NAC组局部和全身症状均明显减轻。 Frequency of seroconversion towards A/H1N1 Singapore 6/86 influenza virus was similar in the two groups, but only 25% of virus-infected subjects under NAC treatment developed a symptomatic form, versus 79% in the placebo group. Evaluation of cell-mediated immunity showed a progressive, significant shift from anergy to normoergy following NAC treatment. Administration of N-acetylcysteine during the winter, thus, appears to provide a significant attenuation of influenza and influenza-like episodes, especially in elderly high-risk individuals. N-acetylcysteine did not prevent A/H1N1 virus influenza infection but significantly reduced the incidence of clinically apparent disease. ER -